# US 2022/0031757 A1 · Method for repairing damaged tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031757 A1
- Document ID: US20220031757A1
- Status: Published application
- Kind: A1
- Application number: 17/503,756
- Filed: 2021-10-18
- Published: 2022-02-03
- Earliest claimed: 2016-12-28
- Assignees: Two Cells Co., Ltd.; Hiroshima University
- Applicants: TWO CELLS Co., Ltd.; Hiroshima University
- Inventors: Yukio Kato; Koichiro Tsuji; Ayumu Nakashima; Takao Masaki; Shigehiro Doi; Ken Yoshida
- Web page: https://patentgrep.com/patent/US20220031757A1

## CPC

- A61K 35/19: Platelets; Megacaryocytes
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0662: {Stem cells}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2500/99: Serum-free medium
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/135: Platelet-derived growth factor [PDGF]
- C12N 2501/999: Small molecules not provided for elsewhere
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In order to provide (i) a repair agent for damaged tissue and (ii) a method for producing the repair agent, the present invention uses mesenchymal stem cells cultured in a serum-free medium.

## Claims

### Claim 1

A method for repairing damaged tissue, comprising administering to the damaged tissue a repair agent comprising mesenchymal stem cells cultured in a serum-free medium, wherein the damaged tissue is tissue damage that accompanies chronic renal failure, a chronic kidney disease, cirrhosis, viral hepatitis, alcoholic hepatitis, or non-alcoholic steatohepatitis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the repair agent is intended to suppress fibrosis of a living tissue.

### Claim 3 (depends on 1)

The method of claim 1, wherein the repair agent is intended to suppress infiltration of an inflammatory cell.

### Claim 4 (depends on 1)

The method of claim 1, wherein the repair agent is intended to control activity of a macrophage.

### Claim 5 (depends on 1)

The method of claim 1, wherein the serum-free medium contains an FGF, a PDGF, an EGF, at least one phospholipid, and at least one fatty acid.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mesenchymal stem cells are mesenchymal stem cells which have been selected by screening and are non-tumorigenic.

### Claim 7 (depends on 1)

The method of claim 1, wherein the mesenchymal stem cells have been subcultured at least once.

### Claim 8 (depends on 7)

The method of claim 7, wherein the mesenchymal stem cells which are being subcultured are detached with use of a cell detaching agent containing neither a mammal-derived component nor a microorganism-derived component.

### Claim 9 (depends on 1)

The method of claim 1, wherein the mesenchymal stem cells are cultured with use of a culture vessel suitable for culture of the mesenchymal stem cells.
